What is the current Price Target for the Neumora Therapeutics stock?

The average Neumora Therapeutics target price is $12.99. This is 738.15% higher than the current stock price. The highest price target is 1,835.48%, the lowest is 158.06%. 8 Analysts have issued a price target Neumora Therapeutics 2026 .

How high will the Neumora Therapeutics stock rise?

No reliable answer can be given as to how high the Neumora Therapeutics stock will rise. The performance of stocks, including the Neumora Therapeutics stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Neumora Therapeutics stock today?

The performance of Neumora Therapeutics stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Neumora Therapeutics stock fall?

The decline in Neumora Therapeutics stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Neumora Therapeutics Forecast, price target & analysts

$1.57

0.97% today

Nasdaq, Feb 28, 07:50 pm CET

ISIN

US6409791000

Symbol

NMRA

Reports

Quarter | Annual

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Neumora Therapeutics Target price 2025 - Analyst rating & recommendation

Neumora Therapeutics Classifications & Recommendation:

Buy

78%

Hold

22%

Neumora Therapeutics Price Target

Target Price	$12.99
Price	$1.55
Potential	738.15% register free of charge
Number of Estimates	8

	8 Analysts have issued a price target Neumora Therapeutics 2026 . The average Neumora Therapeutics target price is $12.99. This is 738.15% register free of charge higher than the current stock price. The highest price target is $30.00 1,835.48% register free of charge , the lowest is $4.00 158.06% register free of charge .
	A rating was issued by 9 analysts: 7 Analysts recommend Neumora Therapeutics to buy, 2 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Neumora Therapeutics stock has an average upside potential 2026 of 738.15% register free of charge . Most analysts recommend the Neumora Therapeutics stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '23	2024 Estimates
Earnings Per Share $	-1.49	-1.61
	73.26%	8.05%
P/E		negative

5 Analysts have issued a Neumora Therapeutics forecast for earnings per share. The average Neumora Therapeutics <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2023	$-1.49	73.26%
2024	$-1.61 8.05% Unlock
2025	$-1.40 13.04% Unlock
2026	$-1.34 4.29% Unlock
2027	$-1.46 8.96% Unlock
2028	$-0.96 34.25% Unlock

Current	-0.84	95.55%
2024	-0.97 15.48% Unlock
2025	-1.11 14.43% Unlock
2026	-1.16 4.50% Unlock
2027	-1.07 7.76% Unlock
2028	-1.62 51.40% Unlock

Neumora Therapeutics...

Current Neumora Therapeutics Upgrades & Downgrades Beta

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
HC Wainwright & Co.	Locked ➜ Locked	Locked	Feb 14 2025
B of A Securities	Locked ➜ Locked	Locked	Jan 06 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Jan 03 2025
Needham	Locked ➜ Locked	Locked	Jan 02 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Dec 16 2024
RBC Capital	Locked ➜ Locked	Locked	Nov 22 2024
Needham	Locked ➜ Locked	Locked	Nov 13 2024

Analyst Rating	Date
Locked HC Wainwright & Co.: Locked ➜ Locked	Feb 14 2025
Locked B of A Securities: Locked ➜ Locked	Jan 06 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Jan 03 2025
Locked Needham: Locked ➜ Locked	Jan 02 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Dec 16 2024
Locked RBC Capital: Locked ➜ Locked	Nov 22 2024
Locked Needham: Locked ➜ Locked	Nov 13 2024

Discover more stocks with a high price target

Coinbase Global, Inc. 60.51%

BioNTech SE - ADR 30.07%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now